XO1 Overview

  • Founded
  • 2013
  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • M&A

XO1 General Information


Developer of anticoagulant drugs to prevent heart attack and stroke without causing bleeding. The company develops ichorcumab drugs and operates virtually by engaging contract research and development specialists in Europe and the US, managed by a small team of experienced drug developers.

Contact Information

Ownership Status
Financing Status
Formerly VC-backed
Primary Industry
Other Industries
Drug Discovery
Primary Office
  • Moneta Building
  • Babraham Research Campus, Babraham
  • Cambridge CB22 3AT
  • England, United Kingdom
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

XO1 Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Merger/Acquisition 19-Mar-2015 0000 Completed Generating Revenue
1. Early Stage VC (Series A) 17-Jun-2013 0000 0000 Completed Product Development
To view XO1’s complete valuation and funding history, request access »

XO1 Executive Team (3)

Name Title Board Seat Contact Info
Robert Schroff Ph.D Chief Operating Officer
You’re viewing 1 of 3 executive team members. Get the full list »

XO1 Board Members (3)

Name Representing Role Since
Andrew Walsh Self Board Member 000 0000
You’re viewing 1 of 3 board members. Get the full list »

XO1 Former Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Cambridge Enterprise Angel Group Minority 000 0000 000000 0
Index Ventures Venture Capital Minority 000 0000 000000 0
LRM Venture Capital Minority 000 0000 000000 0
Total Medical Ventures Venture Capital Minority 000 0000 000000 0
To view XO1’s complete investors history, request access »